ReviewCurrent cardiology reviews2015
Advanced therapies for end-stage heart failure.
Review in Current cardiology reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Referral Criteria to Palliative Care for Patients With Heart Failure: A Systematic Review.Circulation. Heart failure · 2020Pooled it
- Exosomes derived from microRNA-540-3p overexpressing mesenchymal stem cells promote immune toleranceWorld journal of stem cells · 2024Article
- Mesenchymal Stromal Cell Exosomes in Cardiac Repair.Current cardiology reports · 2022Review
- Clinicopathological correlations in heart transplantation recipients complicated by death or re-transplantation.Frontiers in cardiovascular medicine · 2022Article
- Wharton's Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View.Pharmaceutics · 2021Review
- Left Ventricular Assist Devices in Patients With Active Malignancies.JACC. CardioOncology · 2021Article
- Advance Directives and Factors Associated with the Completion in Patients with Heart Failure.International journal of environmental research and public health · 2021Article
- A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible Blood Propulsion.Annals of biomedical engineering · 2021Article
- Expected vs Actual Outcomes of Elective Initiation of Inotropic Therapy During Heart Failure Hospitalization.Mayo Clinic proceedings. Innovations, quality & outcomes · 2020Article
- Donor and Recipient Characteristics in Heart Transplantation Are Associated with Altered Myocardial Tissue Structure and Cardiac Function.Radiology. Cardiothoracic imaging · 2019Article
- Generation of bioartificial hearts using decellularized scaffolds and mixed cells.Biomedical engineering online · 2019Article
- Cardiac Assist Devices: Early Concepts, Current Technologies, and Future Innovations.Bioengineering (Basel, Switzerland) · 2019Review
- Ethical Considerations in the Long-Term Ventricular Assist Device Patient.Current heart failure reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of the advanced heart failure patient can be complex. Therapies include cardiac transplantation and mechanical circulatory support, as well inotropic agents for the short-term. Despite a growing armamentarium of resources, the clinician must carefully weigh the risks and benefits of each therapy to develop an optimal treatment strategy. While cardiac transplantation remains the only true "cure" for end-stage disease, this resource is limited and the demand continues to far outpace the supply. For patients who are transplant-ineligible or likely to succumb to their illness prior to transplant, ventricular assist device therapy has now become a viable option for improving morbidity and mortality. Particularly for the non-operative patient, intravenous inotropes can be utilized for symptom control. Regardless of the treatments considered, care of the heart failure patient requires thoughtful dialogue, multidisciplinary collaboration, and individualized care. While survival is important, most patients covet quality of life above all outcomes. An often overlooked component is the patient's control over the dying process. It is vital that clinicians make goals-of-care discussions a priority when seeing patients with advanced heart failure. The use of palliative care consultation is well-validated and facilitates these difficult conversations to ensure that all patient needs are ultimately met.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.